DERIVATION OF A SHORT FORM OF THE NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE-25 IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	DERIVATION OF A SHORT FORM OF THE NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE-25 IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Συγγραφείς:	Singerman L; Retina Associates of Cleveland, Inc, Cleveland, Ohio., Gugiu C; Clinical Outcomes Solutions Ltd, Tucson, Arizona., Tschosik E; Genentech, Inc, South San Francisco, California., Doll H; Clinical Outcomes Solutions Ltd, Folkestone, United Kingdom; and., Singerman B; Intercare Behavioral Health, Pittsburgh, Pennsylvania., Gentile B; Genentech, Inc, South San Francisco, California.
Πηγή:	Retina (Philadelphia, Pa.) [Retina] 2025 Dec 01; Vol. 45 (12), pp. 2319-2328.
Τύπος έκδοσης:	Journal Article
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8309919 Publication Model: Print Cited Medium: Internet ISSN: 1539-2864 (Electronic) Linking ISSN: 0275004X NLM ISO Abbreviation: Retina Subsets: MEDLINE
Imprint Name(s):	Publication: Hagerstown, MD : Lippincott Williams & Wilkins Original Publication: Philadelphia : Lippincott, [1981?-
Ιατρικοί όροι (MeSH):	Visual Acuity/physiology , Wet Macular Degeneration/physiopathology , Wet Macular Degeneration/drug therapy , National Eye Institute (U.S.) , Sickness Impact Profile* , Quality of Life*, Angiogenesis Inhibitors/therapeutic use ; Ranibizumab/therapeutic use ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Humans ; Psychometrics ; Female ; Male ; Surveys and Questionnaires ; Aged ; Reproducibility of Results ; United States ; Aged, 80 and over ; Middle Aged ; Intravitreal Injections
Περίληψη:	Purpose: Develop a short form of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) using Rasch methodology in patients with neovascular age-related macular degeneration. Methods: Data on 32 items of the NEI VFQ-25 were analyzed from 1,294 patients in 3 studies of ranibizumab in neovascular age-related macular degeneration. Items were first grouped by visual function type; iterative multiple-group rating scale Rasch analyses were used to derive the Visual Function Questionnaire-Short Form (VFQ-SF). Item and scale-level VFQ-SF psychometric properties were assessed with estimation of meaningful within-patient change. Results: Fourteen of 32 items were eliminated initially; the final optimal subset included 7 items measuring 5 domains. The seven-item VFQ-SF had strong internal consistency (average item-total correlation 0.67, Cronbach alpha 0.88), test-retest reliability (intraclass correlation coefficient 0.79-0.91), and high NEI VFQ-25 composite score correlation (r = 0.93). Convergent (mean r = 0.76) and divergent (mean r = 0.24) validity were demonstrated. Known-groups validity was shown by mean VFQ-SF scores monotonically increasing with best-corrected visual acuity severity categories with large between group effect sizes (>2.8). Responsiveness was confirmed with VFQ-SF change linearly related to best-corrected visual acuity change. A meaningful within-patient change estimate of seven points was derived. Conclusion: The seven-item VFQ-SF measures composite vision-related functioning, met all psychometric benchmarks, and is fit-for-purpose in neovascular age-related macular degeneration patients. (Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Ophthalmic Communications Society, Inc.)
References:	Arch Ophthalmol. 1984 Nov;102(11):1640-2. (PMID: 6208888) Pharmacoeconomics. 2002;20(12):791-812. (PMID: 12236802) Invest Ophthalmol Vis Sci. 2011 May 18;52(6):3354-9. (PMID: 21282568) Stat Med. 1987 Jan-Feb;6(1):79-90. (PMID: 3576020) Med Care. 1989 Mar;27(3 Suppl):S178-89. (PMID: 2646488) Am J Manag Care. 2019 Jul;25(10 Suppl):S172-S181. (PMID: 31419088) Value Health. 2011 Dec;14(8):1101-8. (PMID: 22152180) Qual Life Res. 2012 Mar;21(2):323-34. (PMID: 21814877) Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3629-35. (PMID: 19255158) Ophthalmology. 1992 Jun;99(6):933-43. (PMID: 1630784) Ophthalmology. 1995 Feb;102(2):205-10. (PMID: 7862408) Ophthalmology. 2007 Oct;114(10):1804-9. (PMID: 17908590) J Clin Epidemiol. 2008 Feb;61(2):102-9. (PMID: 18177782) PLoS One. 2013 Sep 12;8(9):e73084. (PMID: 24069172) Invest Ophthalmol Vis Sci. 2010 Feb;51(2):712-7. (PMID: 19797233) Lancet. 2012 May 5;379(9827):1728-38. (PMID: 22559899) Psychol Bull. 1979 Mar;86(2):420-8. (PMID: 18839484) Am J Epidemiol. 1977 Jul;106(1):17-32. (PMID: 879158) J Rheumatol. 2011 Aug;38(8):1759-64. (PMID: 21807798) Acta Ophthalmol. 2020 Sep;98(6):618-626. (PMID: 32189476) Int J Public Health. 2013 Aug;58(4):637-42. (PMID: 23089674) Health Qual Life Outcomes. 2006 Oct 11;4:79. (PMID: 17034633) Health Qual Life Outcomes. 2006 Sep 27;4:70. (PMID: 17005038)
Contributed Indexing:	Keywords: Visual Function Questionnaire-Short Form; neovascular age-related macular degeneration; psychometric
Substance Nomenclature:	0 (Angiogenesis Inhibitors) ZL1R02VT79 (Ranibizumab) 0 (Vascular Endothelial Growth Factor A)
Entry Date(s):	Date Created: 20251114 Date Completed: 20251114 Latest Revision: 20251217
Update Code:	20260130
PubMed Central ID:	PMC12637139
DOI:	10.1097/IAE.0000000000004625
PMID:	41236117
Βάση Δεδομένων:	MEDLINE

Full Text Finder

Περιγραφή
ISSN:	1539-2864
DOI:	10.1097/IAE.0000000000004625